12 results about "Mirna target" patented technology

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

Provided herein are compositions and methods for treatment of Amyotrophic Lateral Sclerosis as well as Spinocerebellar Ataxia Type 2 by way of reducing levels of the ATXN2 gene expression. More specifically. miRNA compositions that target ATXN2 are able to reduce ATXN2 levels.

The present application relates to the technical field of spleen delivery, and specifically discloses a spleen precise expression composition, a vaccine composition and application thereof. The spleen precise expression composition comprises: component (1): at least one nucleic acid comprising a nucleotide sequence encoding a target protein and one or more miRNA targeting binding sequences; component (2): a lipid nanoparticle composition which is easy to accumulate in the spleen. The spleen precise expression composition can be used for preparing a lipid nanoparticle or a drug or vaccine composition, and can be efficiently delivered into the spleen and its tissues and cells, and significantly reduces the expression of target genes in non-spleen organs, avoiding side effects such as inflammatory reactions or other off-target effects caused by undesired expression.

The present disclosure provides miRNA mimics targeting CDK4 and / or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.

The present disclosure provides miRNA mimics targeting CDK4 and / or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.

Microparticles that contain miRNA that controls the production of nitric oxide and are an agent for promoting the production of nitric oxide are new microparticles that enable controlling the expression of a protein and / or a gene related to erectile dysfunction; a preventive drug or a therapeutic drug for erectile dysfunction; a method for improving erectile dysfunction; it is preferable that the microparticles be exosomes; and it is preferable that the microparticles of the present disclosure contain miRNA targeting a gene concerning the expression of nitric oxide synthase as the miRNA that controls the production of nitric oxide, and be an agent for promoting the expression of nitric oxide synthase.

The invention discloses miR-285-3p for preventing and treating spodoptera frugiperda and application of the miR-285-3p. MiRNA, miR-285-3p targeting a key gene for growth and development of the spodoptera frugiperda is screened for the first time, and after an analogue agomiR-285-3p of the miRNA, miR-285-3p is injected, the agomiR-285-3p is found to be capable of inhibiting normal expression of ecdysone induced protein 74EF (Ecdyson-induced protein 74EF, Eip74EF) gene of the spodoptera frugiperda, and the agomiR-285-3p can be used for inhibiting the growth and development of the spodoptera frugiperda. Therefore, the growth and development of the spodoptera frugiperda larvae are slowed down, the feed intake is reduced, and the death rate is increased. In addition, by adding an analogue agomiR-285-3p into the feed, the growth of the spodoptera frugiperda can be inhibited, the food intake is reduced, and the death rate is increased. The invention provides a new target and technical support for establishing a new strategy for preventing and controlling the spodoptera frugiperda based on the miRNA.

The invention discloses miR-2c-5p for preventing and treating spodoptera frugiperda and application of miR-2c-5p. MiRNA and miR-2c-5p targeting a key gene for growth and development of the spodoptera frugiperda are screened for the first time, and after an analogue agomiR-2c-5p of the miRNA and miR-2c-5p is injected, the agomiR-2c-5p is found to be capable of inhibiting normal expression of ecdysone-induced protein 78C (Ecdyson-induced protein 78C, Eip78C) gene of the spodoptera frugiperda, and the agomiR-2c-5p can be used for preventing and treating the spodoptera frugiperda. Therefore, the growth and development of the spodoptera frugiperda larvae are slowed down, the feed intake is reduced, and the death rate is increased. In addition, by adding an analogue agomiR-2c-5p into the feed, the growth of the spodoptera frugiperda can be inhibited, the food intake is reduced, and the death rate is increased. The invention provides a new target and technical support for establishing a new strategy for preventing and controlling the spodoptera frugiperda based on the miRNA.

The present application relates to the technical field of liver drug delivery, and specifically discloses a liver precise expression composition, a vaccine composition and application thereof. The liver precise expression composition comprises: component (1): at least one nucleic acid comprising a nucleotide sequence encoding a target protein and one or more miRNA targeting binding sequences; component (2): a lipid nanoparticle composition which is easy to accumulate in the liver. The liver precise expression composition can be used to prepare a lipid nanoparticle or a vaccine composition, and can be efficiently delivered into the liver and its tissues and cells, and significantly reduces the expression of target genes in non-liver organs, avoiding side effects caused by undesired expression, such as inflammatory reactions or other off-target effects.

The invention discloses miR-13b-5p for preventing and treating spodoptera frugiperda and application of the miR-13b-5p, miRNA and miR-13b-5p targeting a key gene for growth and development of the spodoptera frugiperda are screened for the first time, and after an analogue agomiR-13b-5p of the miRNA and miR-13b-5p is injected, the agomiR-13b-5p is found to be capable of inhibiting normal expression of a juvenile hormone epoxy hydrolase (JHEH) gene of the spodoptera frugiperda, so that the growth and development of the spodoptera frugiperda can be inhibited, and the growth and development of the spodoptera frugiperda can be inhibited. Therefore, the growth and development of the spodoptera frugiperda larvae are slowed down, the feed intake is reduced, and the death rate is increased. In addition, by adding an analogue agomiR-13b-5p into the feed, the growth of the spodoptera frugiperda can be inhibited, the feeding amount is reduced, and the death rate is increased. The invention provides a new target and technical support for establishing a new strategy for preventing and controlling the spodoptera frugiperda based on the miRNA.

The invention discloses miR-13a-3p for preventing and treating spodoptera frugiperda and application of the miR-13a-3p, miRNA and miR-13a-3p targeting a key gene for growth and development of the spodoptera frugiperda are screened for the first time, and after an analogue agomiR-13a-3p of the miRNA and miR-13a-3p is injected, the agomiR-13a-3p is found to be capable of inhibiting normal expression of a juvenile hormone esterase (JHE) gene of the spodoptera frugiperda, so that the growth and development of the spodoptera frugiperda can be inhibited, and the growth and development of the spodoptera frugiperda can be inhibited. Therefore, the growth and development of the spodoptera frugiperda larvae are slowed down, the feed intake is reduced, and the death rate is increased. In addition, by adding the analogue agomiR-13a-3p into the feed, the growth of the spodoptera frugiperda can be inhibited, the feeding amount is reduced, and the death rate is increased. The invention provides a new target and technical support for establishing a new strategy for preventing and controlling the spodoptera frugiperda based on the miRNA.